ESMO 2023 | Monitoring disease progression with HPV cfDNA in head and neck cancer

Jens Peter Klussmann, MD, University of Cologne, Cologne, Germany, discusses the role of human papilloma virus (HPV) cell free DNA (cfDNA) in managing patients with HPV-positive head and neck cancer. By utilizing the viral DNA of HPV found in humans, clinicians can perform assays to monitor disease progression before and after treatment, detect relapse, and perform tumor staging. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.